OncoCyte to Present Interim Data from Its Lung Cancer Diagnostic Test Study at the American Thoracic Society Conference May 2...
January 24 2017 - 7:00AM
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel,
non-invasive tests for the early detection of
cancer, announced that its abstract on interim data from the
Company’s lung cancer diagnostic test study has been selected for
presentation in a poster discussion session at the 2017 American
Thoracic Society (ATS) International Conference in Washington,
D.C. The discussion will be led by Dr. Anil Vachani, an
Associate Professor of Medicine at the Hospital of the University
of Pennsylvania and the Veteran's Administration Medical
Center. The analysis “Multi-Gene Classifier for the Diagnosis
of Benign Versus Malignant Pulmonary Nodules” will be discussed in
the “Pulmonary Nodules and Thoracic Surgery: Working Across the
Aisle” session to take place at 2:15 p.m. on Monday, May 22nd.
ATS is an international medical conference that
is typically attended by more than 16,000 clinicians and industry
representatives. It is considered one of the premier
conferences for Thoracic Surgeons, Pulmonologists and other
clinicians involved in the routine screening and diagnosis of lung
cancer. Approximately half of the attendees come from outside
the United States.
“The data to be presented is from an interim
analysis of prospectively collected patient samples from our
ongoing lung cancer diagnostic study,” said William Annett,
President and Chief Executive Officer of OncoCyte. “Our study
is a follow-up to the Wistar Institute study, which reported a test
sensitivity of 90% and specificity of 62% at the CHEST 2016 Annual
Meeting. We expect to complete our study by the end of the
current quarter. The ATS presentation will be an important
step in our test’s continued development, which, if successfully
completed, is expected to result in the commercial launch of the
test during the second half of this year.”
According to the lead author, Dr. Anil Vachani,
“If the assay continues to perform at the levels reported by
Wistar, it could create a significant improvement in the standard
of care in lung nodule management. Current practice can
result in patients undergoing avoidable invasive procedures, which
a diagnostic test of this type could help to avoid.”
About OncoCyte Corporation
OncoCyte is focused on the development and
commercialization of novel, non-invasive blood and urine (“liquid
biopsy”) diagnostic tests for the early detection of cancer to
improve health outcomes through earlier diagnoses, to reduce the
cost of care through the avoidance of more costly diagnostic
procedures, including invasive biopsy and cystoscopic procedures,
and to improve the quality of life for cancer patients.
While current biopsy tests use invasive surgical
procedures to provide tissue samples in order to determine if a
tumor is benign or malignant, OncoCyte is developing a next
generation of diagnostic tests that will be based on liquid
biopsies using blood or urine samples. OncoCyte’s pipeline products
are intended to be confirmatory diagnostics for lung, bladder and
breast cancer. OncoCyte’s diagnostic tests are being developed
using proprietary sets of genetic and protein biomarkers that are
differentially expressed in specific types of cancer. For more
information visit www.oncocyte.com.
Forward Looking Statements
This press release contains forward-looking
statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates”) are forward-looking statements. These statements
include those pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for OncoCyte, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential diagnostic tests or products,
uncertainty in the results of clinical trials or regulatory
approvals, the need and ability to obtain future capital,
maintenance of intellectual property rights, and the need to obtain
third party reimbursement for patients ’use of any diagnostic tests
we commercialize. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of OncoCyte, particularly those mentioned in
“Risk Factors” found in OncoCyte’s Securities and Exchange
Commission filings. OncoCyte disclaims any intent or obligation to
update these forward-looking statements, except as may be required
by law.
Investor Contact:
EVC Group, Inc.
Michael Polyviou/Doug Sherk
646-445-4800
mpolyviou@evcgroup.com / dsherk@evcgroup.com